| PACKAGING TYPE: | 10x15 Alu-alu (10 Strips In 1 Box) |
| COMPOSITION: | Sitagliptin 100mg+dapagliflozin 10mg |
| FORMULATION: | Tablet |
| Description: | SP TRIO Tablet is an advanced anti-diabetic combination containing Sitagliptin and Dapagliflozin, designed for effective management of type 2 diabetes mellitus. Sitagliptin, a DPP-4 inhibitor, enhances insulin secretion and reduces glucagon levels, while Dapagliflozin, an SGLT2 inhibitor, works by promoting glucose excretion through urine. This dual mechanism helps achieve superior glycemic control, especially in patients not adequately controlled with single or dual therapy. |
| Side Effects: | Common side effects may include: Increased urination Urinary tract infections Thirst or dehydration Nasopharyngitis Headache Serious (rare) side effects: Ketoacidosis (due to Dapagliflozin) Pancreatitis (due to Sitagliptin) Severe urinary or genital infections Hypotension (due to fluid loss) |
| How to Use: | Take the tablet as prescribed by your doctor Usually taken once daily, with or without food Swallow whole with water Maintain proper hydration during treatment Follow recommended diet and exercise plan |
| Precaution: | Not recommended in severe kidney impairment Maintain adequate fluid intake to prevent dehydration Monitor kidney function regularly Use cautiously in elderly patients Inform doctor if you have history of recurrent UTIs or pancreatitis Avoid excessive alcohol consumption Not recommended during pregnancy or breastfeeding without medical advice |
| Product Benefits: | Dual-action formula for better blood sugar control Promotes glucose excretion via kidneys (SGLT2 action) Enhances insulin secretion and reduces glucagon levels Helps in weight management May support cardiovascular and renal health Low risk of hypogly |
Frequently Asked Questions
It is used to control blood sugar levels in patients with type 2 diabetes mellitus using a dual-action mechanism.
It may help reduce weight due to glucose loss through urine (Dapagliflozin effect).
Yes, increased urination is a common effect due to the SGLT2 inhibitor component.




















